{
    "nctId": "NCT06028022",
    "briefTitle": "Reishi Mushroom Extract for Fatigue And/or Arthralgias/myalgias in Patients with Breast Cancer on Aromatase Inhibitors",
    "officialTitle": "Reishi Mushroom Extract for Fatigue And/or Arthralgias in Patients with Breast Cancer on Aromatase Inhibitors: a Randomized Phase II MNCCTN Trial",
    "overallStatus": "RECRUITING",
    "conditions": "Estrogen Receptor-Positive Breast Carcinoma",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "SUPPORTIVE_CARE",
    "enrollmentCount": 80,
    "primaryOutcomeMeasure": "Change in fatigue scores",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Age \u2265 18 years\n* History of breast cancer, estrogen receptor positive (ER+), Her 2 positive or negative\n* Fatigue \u2265 4/10\n* Currently taking any aromatase inhibitor in the curative setting and planning to be on such for at least 8 weeks after registration. (Patients on concurrent ovarian suppression \\[such as with leuprolide acetate, goserelin\\] are allowed)\n* Prior treatment: last chemotherapy \u2265 90 days prior to randomization (if treated with chemotherapy)\n* On a stable dose of pain medications if pain medications are being regularly used. (i.e., no change in dosage in the past 30 days)\n* If on supplements, must be on stable dose with no plan to change; not on or planning any acupuncture or other specific supportive modalities for fatigue or AI arthralgias\n* Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0, 1 or 2\n* White blood cell count (WBC) \u2265 3,000/mm\\^3 (obtained \u2264 30 days prior to randomization)\n* Hemoglobin \u2265 10 g/dL (obtained \u2264 30 days prior to randomization)\n* Platelet count \u2265 100,000/mm\\^3 (obtained \u2264 30 days prior to randomization)\n* Total bilirubin \u2264 1.5 x upper limit of normal (ULN) (obtained \u2264 30 days prior to randomization)\n* Alanine aminotransferase (ALT) or aspartate transaminase (AST) \u2264 1.2 x ULN (obtained \u2264 30 days prior to randomization)\n* Prothrombin time (PT)/activated partial thromboplastin time (aPTT) \u2264 1.5 x ULN (obtained \u2264 30 days prior to randomization)\n* Negative pregnancy test done \u2264 7 days prior to registration, for persons of childbearing potential only\n* Provide written informed consent\n* Ability to complete questionnaires\n* Willing to return to enrolling institution during the active monitoring phase of the study\n\nExclusion Criteria:\n\n* Other known uncontrolled medical conditions causing fatigue such as untreated thyroid disease, depression, fibromyalgia, chronic fatigue syndrome, infection, autoimmune disease, or active/untreated hepatitis\n* Allergy to mushrooms\n* On anticoagulation medication or aspirin or having a known bleeding disorder\n* On any specific medication for fatigue (e.g., methylphenidate)\n* Metastatic cancer diagnosis (history of nodal metastases is allowed)\n* Chronic steroid use, unless on physiologic replacement doses\n* Current use of any medical mushrooms\n* On medications for diabetes\n* History of symptomatic hypotension\n* Taking CYP3A4, CYP2D6 sensitive substrates which can be located at the following link:\n\nhttps://www.fda.gov/drugs/drug-interactions-labeling/healthcare-professionals-fdas-examples-drugs-interact-cyp-enzymes-and-transporter-systems\n\n* Drugs which exhibit either \\>20% inhibition or \\>20% induction of CYP2E1 in vivo, such as: Acetaminophen, Dapsone, Enflurane, Halothane, Isoflurane, \\& Theophylline\n* Taking CDK4/6 inhibitors or olaparib\n* Any of the following because this study involves an agent that has unknown genotoxic, mutagenic and teratogenic effects:\n\n  * Pregnant persons\n  * Nursing persons\n  * Persons of childbearing potential who are unwilling to employ adequate contraception",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}